Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors
Published on 08/07/2025 at 18:07 | prnewswire.co.uk
V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investors Oncode Oncology Bridge Fund, Swanbridge and BOMFlindr discovers and develops precision oncology therapeutics with the potential to eradicate tumors in specific patient populationsLead asset is a first-in-class small molecule inhibitor of the cancer driver RNF31View original content:https://www.prnewswire.co.uk/news-releases/precision-oncology-company-flindr-therapeutics-announces-20-million-series-a-financing-to-advance-first-in-class-small-molecule-inhibitors-302125105.html
en | boerse | 67941320 |
